Mineralys Therapeutics, a small drug developer, said on Monday that his experimental medicine, Lorundrostat, the blood pressure considerably reduced in two different studies, giving the medicine a path to market.
Shares in the drug maker rose 33% to $ 14 in pre-market trade.
Lorundrostat represents a new twist on an old approach: blocking the hormone balance, which helps regulate blood pressure, liquid and electrolyte balance. Spironolacton, the original aldosterone inhibitor, was approved in 1960 and has been demonstrated Reduce deaths in patients with heart failure. But the use of spironolacton is limited: it can cause worrying high potassium mirrors, and also unpleasant side effects, including breast growth in men, because the drug can also block the effects of testosterone.
This article is exclusive to Stat+ subscribers
Unlock this article – plus daily coverage and analysis of the biotech sector – by subscribing to Stat+.
Do you already have an account? Log in
View all plans
To read the rest of this story, subscribe to Stat+.
Subscribe